PIM
ALNY icon

Platinum Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Platinum Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,021
Closed -$1.42M – 124
2020
Q1 		$1.42M Sell
13,021
-2,720
-17% -$314K 0.04% 86
2019
Q4 		$1.81M Sell
15,741
-6,914
-31% -$689K 0.04% 66
2019
Q3 		$1.82M Hold
22,655
– – 0.04% 63
2019
Q2 		$1.64M Buy
+22,655
New +$1.74M 0.04% 72

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Platinum Investment Management's ALNY Position: Q2 2020 in Review

Platinum Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 13,021 shares — an estimated $1.42M sold.

Platinum Investment Management first reported a position in ALNY in Q2 2019 and held it in 4 quarters. The position peaked at $1.82M in Q3 2019. 374 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

  • Platinum Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Platinum Investment Management sold 13,021 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $1.42M.
  • Platinum Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Platinum Investment Management's Alnylam Pharmaceuticals position peaked at $1.82M in Q3 2019.
  • 374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on Platinum Investment Management's 13F filing for Q2 2020, filed 6 Aug 2020.